We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Latest addition to Alcon’s intraocular lens (IOL) portfolio expands surgeons’ presbyopia-correcting IOL (PC-IOL) offerings Vivity X-WAVE technology delivers extended range of vision while...
GAMCO Investors, Inc. (NYSE:GBL) (“GAMCO”) announced today that representatives of Associated Capital Group, Inc. (NYSE:AC), its recently completed spin-off, will be commemorating the new...
Magenta Medical, Developer of Novel Heart Failure Therapy, Secures $4 Million in Seed Round from Pitango Venture Capital Magenta Medical, Developer of Novel Heart Failure Therapy, Secures $4...
International orthopedic devices company Wright Medical Group (WMGI) recently reported that its Board of Directors chose Mr. Robert J. Palmisano as President and CEO, starting from September 17...
The Zacks Analyst Blog Highlights: Alcon, Novartis AG, Lazard, Celgene and Elan PR Newswire CHICAGO, April 11, 2011 CHICAGO, April 11, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks...
Novartis (NVS) recently announced amendment to its supplemental new drug application (sNDA) for Afinitor tablets. Afinitor is currently marketed for the treatment of advanced renal cell...
Watson Pharmaceuticals Inc. (WPI) said Alcon Inc. (ACL) filed a lawsuit to challenge its application for a generic version of an eye antibiotic. Units of Alcon on Thursday sought to stay Watson's...
Alcon Inc. (ACL) recently announced that its shareholders have approved of the company’s merger with Novartis AG (NVS). Per the terms of the merger agreement, Alcon shareholders will...
Alcon, Inc. (NYSE:ACL) announced that its shareholders approved the merger of Alcon into Novartis AG at its Annual General Meeting of Shareholders. Under the terms of the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions